Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
Rhea-AI Summary
Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, has announced upcoming presentations at two major healthcare investor conferences. CEO Wes Kaupinen will present at the Cantor Global Healthcare Conference on September 4, 2025, at 2:45 PM ET and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 10:30 AM ET.
The presentations will be accessible via live webcast on Palvella's website, with replays available for approximately 90 days afterward.
Positive
- None.
Negative
- None.
News Market Reaction – PVLA
In the Aug 28 session, PVLA declined 9.12%, reflecting a notable negative market reaction. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:
Cantor Global Healthcare Conference
Thursday, September 4, 2025, at 2:45pm ET
H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025, at 10:30am ET
A live webcast of both presentations will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
